Articles with Puma Biotechnology
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology
Puma Biotechnology Stock News (PBYI) - Public.com
3 Takeaways from Puma Biotechnology's 2018 Earnings | The Motley Fool
Puma Biotechnology
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology Stock News (PBYI) - Page 3 - Public.com
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Puma Biotechnology
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology Has a Simple Plan to Get Back to Growth | The Motley Fool
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting | Business Wire
Puma Biotechnology to Participate in Panel Discussion at Citi's Biotech Conference
Workable Strategic Report on Breast Cancer Therapeutics Drugs
